Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Humeral Head | 2 | 2018 | 2 | 1.54 | Why? |
| Cortical Bone | 2 | 2018 | 7 | 1.53 | Why? |
| Ribonucleotides | 1 | 2020 | 96 | 0.82 | Why? |
| Bone Density | 2 | 2018 | 335 | 0.74 | Why? |
| Oseltamivir | 2 | 2020 | 583 | 0.67 | Why? |
| Postmenopause | 1 | 2018 | 160 | 0.66 | Why? |
| Adenosine Monophosphate | 3 | 2020 | 5652 | 0.54 | Why? |
| Alanine | 3 | 2020 | 5687 | 0.54 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.39 | Why? |
| Amides | 1 | 2020 | 1864 | 0.38 | Why? |
| Aspartylglucosylaminase | 1 | 2006 | 1 | 0.34 | Why? |
| Infusions, Intravenous | 2 | 2020 | 1224 | 0.30 | Why? |
| Antiviral Agents | 7 | 2020 | 41703 | 0.30 | Why? |
| Influenza, Human | 4 | 2020 | 10779 | 0.25 | Why? |
| Equivalence Trials as Topic | 1 | 2020 | 242 | 0.20 | Why? |
| Epiphyses | 1 | 2018 | 6 | 0.20 | Why? |
| Crystallography, X-Ray | 1 | 2006 | 2689 | 0.19 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.18 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.18 | Why? |
| Anal Canal | 1 | 2020 | 367 | 0.17 | Why? |
| Organ Dysfunction Scores | 2 | 2020 | 1475 | 0.16 | Why? |
| Influenza A Virus, H7N9 Subtype | 2 | 2018 | 415 | 0.16 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.15 | Why? |
| Patient Care Planning | 1 | 2020 | 582 | 0.14 | Why? |
| China | 12 | 2021 | 50654 | 0.14 | Why? |
| Pneumonia, Viral | 10 | 2020 | 243684 | 0.13 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.13 | Why? |
| Coronavirus OC43, Human | 1 | 2021 | 1157 | 0.13 | Why? |
| Imaging, Three-Dimensional | 1 | 2018 | 680 | 0.13 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.12 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.12 | Why? |
| Influenza B virus | 1 | 2019 | 815 | 0.12 | Why? |
| Leukocyte Count | 1 | 2021 | 3178 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.11 | Why? |
| Male | 21 | 2021 | 367725 | 0.11 | Why? |
| Severity of Illness Index | 8 | 2021 | 48226 | 0.10 | Why? |
| Female | 21 | 2021 | 380317 | 0.10 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.10 | Why? |
| Aged | 14 | 2021 | 215776 | 0.10 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.10 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.09 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.09 | Why? |
| Muscle Weakness | 2 | 2021 | 406 | 0.09 | Why? |
| Chryseobacterium | 1 | 2006 | 16 | 0.08 | Why? |
| Amidohydrolases | 1 | 2006 | 30 | 0.08 | Why? |
| Influenza A virus | 1 | 2019 | 2234 | 0.08 | Why? |
| Proteome | 1 | 2017 | 1812 | 0.08 | Why? |
| Humans | 26 | 2021 | 930598 | 0.08 | Why? |
| Catalysis | 1 | 2006 | 253 | 0.08 | Why? |
| Proteomics | 1 | 2017 | 2481 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.07 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Substrate Specificity | 1 | 2006 | 639 | 0.07 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.07 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Proportional Hazards Models | 3 | 2021 | 6543 | 0.07 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| Quality of Life | 2 | 2021 | 9820 | 0.06 | Why? |
| Colorectal Neoplasms | 1 | 2017 | 1884 | 0.06 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.06 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.06 | Why? |
| Protein Structure, Secondary | 1 | 2006 | 1077 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Protein Structure, Tertiary | 1 | 2006 | 1565 | 0.06 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.06 | Why? |
| Molecular Structure | 1 | 2006 | 1539 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.05 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.05 | Why? |
| Fatigue | 2 | 2021 | 2479 | 0.05 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.05 | Why? |
| Structure-Activity Relationship | 1 | 2006 | 2219 | 0.05 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.05 | Why? |
| Adult | 11 | 2021 | 244371 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 11367 | 0.05 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 5002 | 0.05 | Why? |
| Walk Test | 1 | 2021 | 461 | 0.05 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2020 | 673 | 0.04 | Why? |
| Barotrauma | 1 | 2018 | 97 | 0.04 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.04 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.04 | Why? |
| Temperature | 1 | 2006 | 2305 | 0.04 | Why? |
| Chromatin | 1 | 2017 | 107 | 0.04 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.04 | Why? |
| Respiratory Syncytial Viruses | 1 | 2020 | 612 | 0.04 | Why? |
| Partial Thromboplastin Time | 1 | 2018 | 436 | 0.04 | Why? |
| Exercise Tolerance | 1 | 2021 | 634 | 0.04 | Why? |
| Glycolysis | 1 | 2017 | 208 | 0.04 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.04 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.04 | Why? |
| Point Mutation | 1 | 2018 | 481 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2018 | 12361 | 0.03 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.03 | Why? |
| Binding Sites | 1 | 2006 | 6201 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Cell Movement | 1 | 2017 | 695 | 0.03 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.03 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Hospital Mortality | 3 | 2020 | 22087 | 0.03 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2019 | 846 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Shock, Septic | 1 | 2020 | 1313 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.03 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2018 | 861 | 0.02 | Why? |
| Protein Binding | 1 | 2006 | 11430 | 0.02 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Hospitals | 2 | 2020 | 11793 | 0.02 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Sleep Wake Disorders | 1 | 2021 | 1463 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Kidney | 1 | 2021 | 3648 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Respiratory System | 1 | 2018 | 3213 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2019 | 4239 | 0.01 | Why? |
| Specimen Handling | 1 | 2019 | 6190 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Viral Proteins | 1 | 2018 | 7370 | 0.01 | Why? |
| Nasopharynx | 1 | 2019 | 10224 | 0.01 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2019 | 22971 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Depression | 1 | 2021 | 14116 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
Wang's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(171)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(310)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_